Get the Stockscreener App
38.01
20.86%
6.56
After Hours:
38.55
0.54
+1.42%
Edgewise Therapeutics Inc stock is traded at $38.01, with a volume of 5.05M.
It is up +20.86% in the last 24 hours and up +14.04% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$31.45
Open:
$39.125
24h Volume:
5.05M
Relative Volume:
5.33
Market Cap:
$4.09B
Revenue:
-
Net Income/Loss:
$-167.80M
P/E Ratio:
-23.29
EPS:
-1.6323
Net Cash Flow:
$-144.07M
1W Performance:
+22.65%
1M Performance:
+14.04%
6M Performance:
+118.83%
1Y Performance:
+129.81%
1-Day Range:
$37.00
$39.96
1-Week Range:
$30.12
$39.96
52-Week Range:
$12.15
$39.96
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
38.01 | 3.38B | 0 | -167.80M | -144.07M | -1.6323 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics Stock Climbs On Catalyst-Rich Pipeline - timothysykes.com
50,000-share sale notice for EWTX (NASDAQ: EWTX) - Stock Titan
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock - Investing.com
Edgewise Therapeutics (EWTX) CMO sells 55,230 shares under 10b5-1 plan - Stock Titan
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong Biotech Sentiment - International Business Times Australia
Edgewise Therapeutics stock hits 52-week high at $39.96 - Investing.com
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules - TradingView
9 new Edgewise hires receive stock options for 266,000 shares - Stock Titan
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Avoiding Lag: Real-Time Signals in (EWTX) Movement - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Why Edgewise Therapeutics stock topped the market on Tuesday - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
This Edgewise Therapeutics Insider Reduced Their Stake By 63% - 富途牛牛
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Edgewise Therapeutics (NASDAQ: EWTX) holder Novo Holdings at 4.98% - Stock Titan
RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX) - The Globe and Mail
EWTX Price Today: Edgewise Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
[ARS] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan
Edgewise Therapeutics (EWTX) outlines 2026 director elections, pay and auditor vote - Stock Titan
Edgewise Therapeutics (EWTX) Stock: What Investors Should Know | Q4 2025: Profit DisappointsStock Market Community - Cổng thông tin điện tử Tỉnh Sơn La
Discipline and Rules-Based Execution in EWTX Response - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month HighHere's What Happened - MarketBeat
Edgewise Therapeutics stock hits 52-week high at 34.03 USD By Investing.com - Investing.com Australia
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 1-Year HighStill a Buy? - MarketBeat
Edgewise Therapeutics stock hits 52-week high at 34.03 USD - Investing.com
Retail Surge: Can Edgewise Therapeutics Inc expand its profit marginsTrade Performance Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Analysts Bullish on Edgewise Therapeutics Stock - National Today
What is the price target for Edgewise Therapeutics (EWTX) Stock | Price at $33.22, Up 1.22%Money Flow - Xã Thanh Hà
Bull Run: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn
Behavioral Patterns of EWTX and Institutional Flows - Stock Traders Daily
Ideas Watch: Will Edgewise Therapeutics Inc stock hit new highs in YEARInsider Selling & Verified Short-Term Trading Plans - baoquankhu1.vn
History Review: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2026 Opening Moves & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Rallies: Can Edgewise Therapeutics Inc grow without dilutionWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Is Edgewise Therapeutics (EWTX) Stock Good for Short Term | Price at $33.00, Up 1.54%Fundamentals - UBND thành phố Hải Phòng
Aberdeen Group plc Increases Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Is Edgewise Therapeutics (EWTX) Stock Suitable for 2026 | Price at $32.50, Down 1.01%MA Crossover - Cổng thông tin điện tử tỉnh Tây Ninh
Aug Wrap: Is Edgewise Therapeutics Inc a cyclical or defensive stockMarket Activity Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
Update Recap: Can Edgewise Therapeutics Inc reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
EWTX - Finviz
Why Edgewise Therapeutics (EWTX) Is Up 8.1% After New Sevasemten BMD Data And Analyst Interest - Sahm
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data - Sahm
EWTX SEC FilingsEdgewise Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Edgewise Therapeutics Inc subject to activist investor interest2026 Action & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
SG Americas Securities Boosts Stake in Edgewise Therapeutics - National Today
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):